Nuo Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: AURX · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1091596
| Field | Detail |
|---|---|
| Company | Nuo Therapeutics, Inc. (AURX) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulation-fd, disclosure
Related Tickers: NURX
TL;DR
Nuo Therapeutics filed an 8-K for a Reg FD disclosure. Details TBD.
AI Summary
Nuo Therapeutics, Inc. filed an 8-K on April 16, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, dollar amounts, or dates beyond the filing date itself.
Why It Matters
This filing indicates Nuo Therapeutics is making a public disclosure under Regulation FD, which ensures all investors receive the same material information simultaneously.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure without immediate financial or operational news.
Key Players & Entities
- Nuo Therapeutics, Inc. (company) — Registrant
- April 16, 2024 (date) — Filing Date
- Regulation FD (regulation) — Disclosure Type
FAQ
What specific information is being disclosed under Regulation FD?
The provided filing excerpt does not specify the content of the Regulation FD disclosure.
When was the earliest event reported in this 8-K?
The earliest event reported is April 16, 2024, which is also the date of the report.
What is Nuo Therapeutics, Inc.'s principal executive office address?
The address is 8285 El Rio, Suite 190, Houston, Texas 77054.
What is Nuo Therapeutics, Inc.'s telephone number?
The telephone number is (346) 396-4770.
What is the SEC file number for Nuo Therapeutics, Inc.?
The SEC file number is 001-32518.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-04-16 17:26:49
Filing Documents
- aurx20240416_8k.htm (8-K) — 20KB
- 0001437749-24-012214.txt ( ) — 137KB
- noticker-20240416.xsd (EX-101.SCH) — 3KB
- noticker-20240416_def.xml (EX-101.DEF) — 10KB
- noticker-20240416_lab.xml (EX-101.LAB) — 14KB
- noticker-20240416_pre.xml (EX-101.PRE) — 10KB
- aurx20240416_8k_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Nuo Therapeutics, Inc. (the "Company") will not file its Annual Report on Form 10-K by April 16, 2024, as previously expected and as reported on its recently filed Form 12b-25. The principal reason for the delay in filing is to allow the Company's independent registered public accounting firm to complete and finalize its review of the Company's audited financial statements for the year ended December 31, 2023. The Company believes the review will be finalized shortly and expects the Form 10-K to be filed no later than April 19, 2024.
Forward-Looking Statements
Forward-Looking Statements This Form 8-K contains forward-looking statements, which are based on management's current expectations or beliefs about the Company's future plans, expectations, and objectives. These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements including, including statements regarding the Company's intention to file the Form 10-K by April 19, 2024. Readers of this Form 8-K are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Chief Financial Officer Date: April 16, 2024